Esteve Pharmaceuticals, S.A.
Esteve Pharmaceuticals, S.A., commonly known as Esteve, is a prominent player in the global pharmaceutical industry, headquartered in Barcelona, Spain. Founded in 1929, Esteve has established itself as a leader in the development of innovative medicines, particularly in the fields of pain management, respiratory diseases, and central nervous system disorders. With a strong presence in Europe and Latin America, Esteve is recognised for its commitment to research and development, resulting in a diverse portfolio of unique products and services. The company’s dedication to quality and innovation has earned it a solid market position, marked by notable achievements in both therapeutic advancements and strategic partnerships. Esteve continues to focus on enhancing patient care through its specialised offerings, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Esteve Pharmaceuticals, S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Esteve Pharmaceuticals, S.A.'s score of 34 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Esteve Pharmaceuticals, S.A.'s reported carbon emissions
In 2023, Esteve Pharmaceuticals, S.A. reported total carbon emissions of approximately 290,716,000 kg CO2e. This figure includes 115,001,000 kg CO2e from Scope 1 emissions, 177,000 kg CO2e from Scope 2 emissions, and a significant 279,038,000 kg CO2e from Scope 3 emissions. The company has shown a trend in emissions over the years, with total emissions recorded at 306,707,000 kg CO2e in 2022, 60,378,000 kg CO2e in 2020, and 31,423,000 kg CO2e in 2011. Notably, the emissions from Scope 1 and 2 have fluctuated, with Scope 1 emissions at 7,927,000 kg CO2e in 2020 and 7,951,000 kg CO2e in 2021. Despite these figures, Esteve Pharmaceuticals has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined reduction commitments suggests a need for further transparency regarding their climate strategy. The company operates within a global context where pharmaceutical firms are increasingly held accountable for their environmental impact, making it essential for Esteve to establish clear climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | 2010 | 2011 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 9,982,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 |
| Scope 2 | 16,014,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000 |
| Scope 3 | 11,963,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Esteve Pharmaceuticals, S.A. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
